Clinical trials
Metastatic Tumor clinical trials
Below are recruiting metastatic tumor clinical trials, each written for real people, not researchers. We’re tracking 580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07524140RecruitingPhase 1
Study of ZE94-0605 for advanced solid tumors
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Kogarah, New South WalesAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT05898399RecruitingPhase 1/Phase 2
Testing ART6043 for advanced cancers with DNA repair defects
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Grand Rapids, MichiganAges 18 years+ - NCT06358677RecruitingPhase 2
Tretinoin cream to prevent skin rash from EGFR drugs
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Salt Lake City, UtahAges 18 years+ - NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT05559853Recruiting
MRI scan study to track brain tumor changes after treatment
This study tests a new MRI (brain scan) method to see how brain tumors change over time after treatment. There are also parts for healthy adults to help with developing and comparing the scan technique.
New York, New YorkAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT04116541RecruitingPhase 2
Targeted therapy for advanced cancer based on tumor genetics
This trial tests different targeted therapies based on the unique genetic changes in your tumor. It is for people with advanced or metastatic cancer who have exhausted standard options and whose tumor has specific genetic markers matched to one of the study drugs.
AngersAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT04443088RecruitingPhase 1
Study drug INV-1120 with or without pembrolizumab for advanced cancers
This Phase 1 trial studies INV-1120 alone and with pembrolizumab (an immune therapy) in adults with advanced solid tumors that have stopped responding to standard treatment or have no standard option. The goal is to see how the treatments work, what dose is safest, and what side effects may occur.
Lafayette, IndianaAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT06689670Recruiting
Liver tumor ablation with a needle-based device
This trial tests a needle-based device that uses heat or cold to destroy liver tumors. It is for people with primary or secondary liver cancer who cannot have surgery or a transplant.
Topkapı, IstanbulAges 18–100 - NCT07062003Recruiting
Minibeam radiation for skin or soft tissue tumors
This trial tests a new type of radiation called minibeam therapy for people with skin or soft tissue cancers that have come back or spread. It's designed to help shrink tumors that standard treatments haven't worked well for, and it uses a special device to focus the radiation more precisely.
Rochester, MinnesotaAges 18 years+ - NCT06521554RecruitingPhase 1
Study of NVL-330 for HER2-altered advanced lung cancer
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Irvine, CaliforniaAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT03842085RecruitingPhase 1
MBS301 drug study for HER2-positive advanced cancers
This Phase 1 study tests MBS301, a new treatment, for people with HER2-positive advanced solid tumors. It mainly looks at safety and how the drug works, especially for cancers that have returned or spread.
ZhengzhouAges 18 years+ - NCT05717166RecruitingPhase 3
Stereotactic radiation for limited metastases with a main tumor
This trial tests whether a precise type of radiation can control cancer that has spread to a limited number of sites (1–10) while you also have the main tumor. It aims to improve outcomes by treating all visible cancer spots with stereotactic ablative radiotherapy.
Prince George, British ColumbiaAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Orange, CaliforniaAges 12 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic tumor?
- Yes. Clin2 currently lists 580 recruiting metastatic tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.